There are currently 93 active clinical trials seeking participants for Sickle Cell Disease research studies. The states with the highest number of trials for Sickle Cell Disease participants are New York, North Carolina, California and Georgia.
MULTIsite Feasibility of MUSIc Therapy to Address Quality Of Life in Sickle Cell Disease
Recruiting
This is a multi-site, multi-visit feasibility RCT of music therapy (MT) among adolescent and adult patients (aged 14 and older) with sickle cell disease (SCD). Subjects will be randomized into one of three groups, either (1) 6 visits of in- person MT (InMT:); (2) 1 visit of in-person MT and 5 visits of virtual MT (HybMT); or (3) 1 visit of in-person health education and 5 visits of virtual health education (HybHE). Cohorts of 15 participants (10 at site 1 and 5 site 2) will be recruited each q... Read More
Gender:
ALL
Ages:
14 years and above
Trial Updated:
05/07/2025
Locations: UH Seidman Cancer Center Adult SCD Clinic or UH Rainbow Babies and Children's Hospital Sickle Cell Anemia Center, Cleveland, Ohio +1 locations
Conditions: Sickle Cell Disease
Losartan for Diffuse Myocardial Fibrosis in Sickle Cell Disease
Recruiting
This study is a pilot, phase II, open-label study of the angiotensin II receptor blocker, losartan, in patients with Sickle Cell Disease (SCD) 6 years or older for 12 months. The investigators will enroll 24 patients with SCD over the course of 1 year with a goal to complete all study procedures in 2 years. The short-term goal is to obtain clinical pilot data regarding the safety and efficacy of losartan in stabilizing or decreasing extracellular volume fraction (ECV) after 12 months of therapy.
Gender:
ALL
Ages:
6 years and above
Trial Updated:
01/27/2025
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Sickle Cell Disease, Diffuse Myocardial Fibrosis
Sickle Cell Disease Biofluid Chip Technology (SCD BioChip)
Recruiting
'Sickle-shaped' anemia was first clinically described in the US in 1910, and the mutated heritable sickle hemoglobin molecule was identified in 1949. The pathophysiology of SCD is a consequence of abnormal polymerization of sickle hemoglobin (HbS) and its effects on red cell membrane properties, shape, and density, and subsequent critical changes in inflammatory cell and endothelial cell function. Our goal is to understand the impact of CMA abnormalities in SCD, by interrogating a number of reco... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/11/2024
Locations: University Hospitals Case Medical Center, Cleveland, Ohio
Conditions: Sickle Cell Disease
Hydroxyurea Exposure Limiting Pregnancy and Follow-Up Lactation
Recruiting
The purpose of this research study is to document and understand the effects of hydroxyurea exposure for women with SCD and their babies, during both gestation and lactation.
Gender:
ALL
Ages:
All
Trial Updated:
03/09/2023
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Sickle Cell Disease, Sickle Cell Anemia
The Efficacy and Safety of Rilzabrutinib in Patients Aged 10 to 65 Years With Sickle-cell Disease
Recruiting
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group, group-sequential study (Part A), followed by an open-label LTE period (Part B) to investigate the efficacy, and safety of rilzabrutinib in participants with sickle-cell disease (SCD). Study details include: * Study duration: a 52-week double-blind period (Part A), followed by an open-label LTE period (Part B). Double-blind period has two parts, 50% (adult only) until the interim analysis, and 50% (adu... Read More
Gender:
ALL
Ages:
Between 10 years and 65 years
Trial Updated:
05/26/2025
Locations: Bioresearch Partners- Site Number : 8400005, Hialeah, Florida +1 locations
Conditions: Sickle Cell Disease
Blood Sampling for Research Related to Sickle Cell Disease
Recruiting
This study will collect representative blood samples from healthy children and adults and from children and adults who have unique red blood cell features that are related to sickle cell disease. Sickle cell disease is a blood disease that limits the ability of red blood cells to carry oxygen throughout the body. The purpose of the study is to collect a variety of blood samples that may then be used to investigate advances and potential new drug treatments for sickle cell disease. Volunteers mu... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
05/24/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Sickle Cell Trait, Sickle Cell Disease, Sickle Cell Anemia
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
Recruiting
Background: Blood disorders like sickle cell disease and malaria affect many people around the world. Researchers want to learn more about blood disorders. To do this, they need to collect biological samples from people with blood disorders. They also need to collect samples from healthy people. Objective: To collect samples to use for research on blood disorders. Eligibility: People ages 18-70 who have blood disorders. Healthy volunteers without blood disorders are also needed. Design: P... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
05/24/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Sickle Cell Disease, Malaria, Human Physiology, Alpha and Beta Thalassemia
A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)
Recruiting
The main purpose of this study is to compare the effect of tebapivat versus placebo on anemia and to detect a dose-response for hemoglobin (Hb) response in participants with SCD.
Gender:
ALL
Ages:
16 years and above
Trial Updated:
05/21/2025
Locations: Icahn School of Medicine at Mt. Sinai, New York, New York
Conditions: Sickle Cell Disease
Study to Understand the Genetic Risk of Developing an Immune Response After Blood Transfusions Among Individuals With Sickle Cell Disease
Recruiting
The purpose of this research study is to look at genes and determine how they interact with each other to find changes that could explain why some people's immune systems may respond to blood transfusions. This response is called an alloimmune response. We strongly believe that when someone has an alloimmune response, it is caused by changes in their genes. We plan to compare changes in the genes of individuals that develop red blood cell alloimmunization after blood transfusions with those that... Read More
Gender:
ALL
Ages:
Between 2 years and 99 years
Trial Updated:
05/21/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Sickle Cell Disease
A Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease
Recruiting
A randomized control trial in 20 subjects with sickle cell disease comparing oral THU-decitabine to nicotinamide and in combination (THU, decitabine and nicotinamide).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2025
Locations: University of Illinois at Chicago College of Medicine, Chicago, Illinois
Conditions: Sickle Cell Disease
Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
Recruiting
This is a follow-up trial to NYMC 526 (NCT01461837) to assess the safety, efficacy and toxicity of administering Defibrotide prophylaxis for high-risk sickle cell or beta thalassemia patients undergoing a familial haploidentical allogeneic stem cell transplantation with CD34 enrichment and T-cell addback. This patient population historically has a risk of developing sinusoidal obstructive syndrome (SOS) and Defibrotide has demonstrated efficacy in treatment of SOS. The Funding Source is FDA OOPD... Read More
Gender:
ALL
Ages:
Between 6 months and 34 years
Trial Updated:
05/20/2025
Locations: University of California Los Angeles, Los Angeles, California +3 locations
Conditions: Sickle Cell Disease
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
Recruiting
A phase III, multi-center, randomized, placebo-controlled, double-blind study to assess efficacy and safety of crizanlizumab (5 mg/kg) versus placebo, with or without hydroxyurea/hydroxycarbamide therapy, in adolescent and adult Sickle Cell Disease patients with frequent vaso-occlusive crises.
Gender:
ALL
Ages:
Between 12 years and 100 years
Trial Updated:
05/19/2025
Locations: Childrens National Hospital, Washington, District of Columbia +10 locations
Conditions: Sickle Cell Disease